An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder

Published:2016-05 Issue:3 Volume:31 Page:134-146
ISSN:0268-1315
Container-title:International Clinical Psychopharmacology
language:en
Short-container-title:International Clinical Psychopharmacology

Author:

Carrasco José L.,Kornstein Susan G.,McIntyre Roger S.,Fayyad Rana,Prieto Rita,Salas Maribel,Mackell Joan,Boucher Matthieu

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference45 articles.

1. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder

2. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

3. An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

4. Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

5. An Evaluation of Sexual Functioning in Employed Outpatients with Major Depressive Disorder Treated with Desvenlafaxine 50mg or Placebo

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Baseline Cognitive Function Predict the Reduction Rate in HDRS-17 Total Scores in First-Episode, Drug-Naïve Patients with Major Depressive Disorder?;Neuropsychiatric Disease and Treatment;2024-02

2. Novel Quality Control Metric for the Pharmacotherapy of Major Depressive Disorder;The Journal of Clinical Psychiatry;2024-01-03

3. Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper;Expert Opinion on Pharmacotherapy;2023-07-23

4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran;NeuroPsychopharmacotherapy;2022

5. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran;NeuroPsychopharmacotherapy;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3